Silo Pharma, Inc. 8-K

What Happened

• Silo Pharma, Inc. filed a Certificate of Change with the Nevada Secretary of State on June 1, 2026 to effect a 1-for-15 reverse split of its common stock. The Reverse Stock Split became effective at 4:01 p.m. ET on June 2, 2026, and the company’s common stock began trading on a split-adjusted basis when Nasdaq opened on June 3, 2026. The Company’s par value per share remains $0.0001.

Key Details

• Reverse ratio: 1-for-15 (every 15 pre-split shares automatically reclassified into 1 post-split share).
• Authorized common shares after split: 6,666,667.
• No fractional shares were issued; holdings that would have resulted in fractions were rounded up to the next whole share.
• Outstanding stock options, warrants and shares reserved under equity plans were adjusted proportionately; trading symbol remains “SILO” but a new CUSIP was assigned (82711P 300).
• Certificate of Change is filed as Exhibit 3.1 to the Form 8-K (filed June 3, 2026).

Why It Matters

• The reverse split reduces the number of outstanding shares by a 15-to-1 factor and consolidates the share base, which changes per‑share metrics and the share count reported to investors.
• Adjustments to option/warrant exercise prices and plan reserves preserve holders’ economic positions on a post-split basis.
• Continued trading on the Nasdaq Capital Market under the same ticker means market access and visibility are maintained; the new CUSIP identifies the consolidated shares.